Please ensure Javascript is enabled for purposes of website accessibility
Recent News
Home / Wire Stories / Johnson & Johnson loses Remicade patent on appeal

Johnson & Johnson loses Remicade patent on appeal

Johnson & Johnson’s patent on its top-selling arthritis drug Remicade is invalid, a U.S. appeals court ruled Tuesday in a defeat to the drugmaker that just last week lost a patent on another blockbuster medicine. The antibodies covered by this patent were already disclosed in an earlier patent, the U.S. Court of Appeals for the Federal ...

About Bloomberg News

Leave a Reply